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Cardiolipin oxidation and degradation by different factors under severe cell stress serve as a trigger for genetically encoded cell
death programs. In this context, the interplay between cardiolipin and another mitochondrial factor—cytochrome c—is a key
process in the early stages of apoptosis, and it is a matter of intense research. Cytochrome c interacts with lipid membranes by
electrostatic interactions, hydrogen bonds, and hydrophobic effects. Experimental conditions (including pH, lipid composition,
and post-translational modifications) determine which specific amino acid residues are involved in the interaction and influence
the heme iron coordination state. In fact, up to four binding sites (A, C, N, and L), driven by different interactions, have been
reported. Nevertheless, key aspects of the mechanism for cardiolipin oxidation by the hemeprotein are well established. First,
cytochrome c acts as a pseudoperoxidase, a process orchestrated by tyrosine residues which are crucial for peroxygenase activity
and sensitivity towards oxidation caused by protein self-degradation. Second, flexibility of two weakest folding units of the
hemeprotein correlates with its peroxidase activity and the stability of the iron coordination sphere. Third, the diversity of the
mode of interaction parallels a broad diversity in the specific reaction pathway. Thus, current knowledge has already enabled the
design of novel drugs designed to successfully inhibit cardiolipin oxidation.
1. Introduction
Mitochondria—the so-called powerhouses of the cell—are
responsible for a broad assortment of metabolic processes.
Their key role in cells is reflected by the cornucopia of pro-
teins involved in its function. In total, more than 1150 genes
related to organelle function are recorded in the human
MitoCarta. Furthermore, 1 in every 5000 people are effected
by a mitochondrial disorder [1].
Mitochondria play a significant role in cell homeostasis
by helping to modulate cell signaling pathways. On one
hand, the activity of the electron transport chain (ETC)
is related to the release of reactive oxygen species (ROS)
[2] which are strong modifiers of cell constituents such
as proteins, nucleic acids, and lipids. Dysregulation of
ROS can lead to oxidative stress which in turn can initiate
cell death programs [3, 4], in which lipid peroxidation and
their products play a key role [5].
Cardiolipin (CL) oxidation by cytochrome c (Cc) at the
onset of apoptosis is a decisive step [6]. During homeostasis,
the soluble cationic hemeprotein is located in the mitochon-
drial intermembrane space, shuttling electrons between com-
plexes III (CIII) and IV (CIV) in the ETC. Indeed, Cc is a key
Janus catalyst of CL signaling rather than a passive messen-
ger. Its ability to oxidize superoxide anions (O2
-•) to molecu-
lar O2 along with its peroxidase activity in solution reduce the
damage caused by oxidative stress [7–12]. However, rear-
rangement of the mitochondrial membrane triggered by t-
Bid upon severe stress makes CL available to bind Cc [13]
on the outer leaflet of the IMM. Thus, acyl chains of CL are
oxidized due to the oxygenase activity of the hemeprotein
[14]. In fact, oxygenase activity of Cc rises substantially in
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Cc-CL complexes [15]. Subsequent CL oxidation favors the
release of Cc into the cytosol where it triggers apoptosis
[16–18]. Furthermore, an array of products from Cc-medi-
ated CL oxidation—e.g., hydroxy-, oxo-, and peroxipolyun-
saturated fatty acids—act as cell fate decision signals [19].
Although major features of cell death signaling path-
ways converging on CL metabolism have been thoroughly
characterized, understanding the intimate mechanism of CL
oxidation by Cc remains challenging. Both CL-containing
membranes and Cc display complex behaviors that depend
on different factors, including experimental conditions and
post-translational modifications (PTM) of the protein.
This review article aims to provide the readers with an
overview of the interaction between Cc and CL and how it
affects the peroxidase and oxygenase activities of the
hemeprotein. Particular emphasis will be made on the
conformational plasticity of Cc, which enables its Janus
functionality. In addition, we will discuss free oxidation
of CL, regulation of Cc activity, and its relationship with
a diverse range of human diseases and recent strategies
to combat them.
2. Cardiolipin: Properties and Role in the
Mitochondrial Membranes
Cardiolipins (1,3-bis(sn-3′-phosphatidyl)-sn-glycerol) are a
group of anionic phospholipids found in the plasma mem-
brane of various bacteria and the inner mitochondrial
membrane of eukaryotic cells [20]. These lipids contain
two 1,2-diacyl-sn-glycero-3-phos-phoryl moieties bridged
by a glycerol molecule. The two phosphatidyl groups are
stereochemically nonequivalent, being respectively in pro-
R and pro-S positions with respect to carbon 2 in the
bridge [21]. The presence of 4 acylation sites—a fifth one
at the central carbon of the glycerol bridge is also possi-
ble—would be consistent with a diverse range of CL spe-
cies according to the distinct acyl chains available in a
given organism. In humans, for instance, we would expect
144 CL derivatives. This contrasts with the rather lower
diversity of CL compounds found in each organism [22].
Despite the presence of two phosphate groups in CL, it
is thought that the single anionic species predominates. In
this species, one proton is shared through a bicyclic reso-
nance structure involving the central hydroxyl group [23].
In membranes, the glycerol hydroxyl forms intra- and
interlipid hydrogen bonds with oxygen atoms from phos-
phate, not with carbonyl groups [24]. Early measurements
of ionization constants yielded a first pKA value of 2.8
and a second one in the range between 7.5 and 9.5. A
recent fourier transform infrared spectroscopy (FT-IR)
analysis on liposomes also suggests two ionization steps
with pKA values 4.7 and 7.9 [25, 26]. Density functional
theory level computations indicate a wide gap between the
two pKA values [27]. Other results indicate the opposite:
both behave as strong dibasic acids with pKA values within
the pH range 2-3 in solution [28] and membrane prepara-
tions [29, 30]. According to this data, membrane-embedded
CL carries two negative charges at physiological pH values.
The behavior of CL-containing membranes is complex
and strongly dependent on the composition [31] and
experimental/simulation conditions [32]. For instance, the
selected CL protonation state in deterministic simulations
can influence results. Thermodynamic analyses with lipid
mono- and bilayers indicate a decrease in the area com-
pressibility modulus [33]. According to molecular dynamics
(MD) simulations, their thickness—measured as interpho-
sphate distances—decreases with CL content, as the elec-
tron density does [24, 34]. Furthermore, small-angle X-ray
scattering (SAXS) and neutron scattering (SANS) have con-
firmed that CL-containing bilayers have a lower thickness.
This may reflect the smaller head-group volume per phos-
phate. However, these membranes show larger distances
between electron density maxima and a thicker hydrocar-
bon moiety [24]. Comparison of different MD trajectories
of bilayers with PDB files suggests conformational selection
takes place when CLs bind to membrane proteins [34]. The
negative charge of CL and its four acyl groups strongly
affect the phase preference of the lipid, which varies from
lamellar (Lα) to inverted hexagonal (HII) depending on
pH [30, 32].
CL is essential for the functionality of mitochondrial
membranes and processes taking place therein—e.g., protein
import and electron transport [6]. It represents between 5%
and 20% of the total lipid content of the inner mitochondrial
membrane (IMM) and is more abundant in the internal leaf-
let [35, 36] (Figure 1(a)). CL acts on membrane components
of the ETC, aiding the assembly of the so-called respiratory
supercomplexes [37, 38]. Supercomplexes modulate the
performance of mitochondrial electron transport and oxi-
dative phosphorylation [39]. Reportedly, CL is able to trap
protons [40, 41], and it has been hypothesized to be impor-
tant in the mechanism of CIII and IV acting as a proton
exchanger [42–44]. The absence and/or modification of
CL cause the development of several pathologies such as
Barth’s syndrome [37, 45–48]. Indeed, alteration of the
IMM due to a decrease in the content of CL disrupts the
ETC, increasing the generation of ROS [49] (Figure 1(b)).
Remarkably, CL can be oxidized directly by ROS such as
hydroxyl radicals and singlet oxygen, acting the products
as proapoptotic signals [50].
CL is a mitochondrial stress-signaling factor in mito-
phagy and both the intrinsic and extrinsic apoptotic path-
ways [6, 51]. Under stress conditions (e.g., treatment with
rotenone, staurosporine or cyclosporine A, and autopha-
gic or apoptotic stimuli), CL molecules flip from the
IMM to the outer mitochondrial membrane (OMM)
[52–54] (Figure 1(b)). When eliciting the extrinsic apo-
ptotic pathway in lymphoblastoid cells (type II cells)
derived from Barth’s syndrome patients and tafazzin
knock-down HeLa cells, CL microdomains on the OMM
recruit procaspase-8 to promote its activation [55, 56]. When
caspase-8 becomes active, it cleaves the proapoptotic factor
Bid, a BH3-only member of the Bcl-2 family [56]. The active
C-terminal fragment of the Bid (t-Bid) targets CL or its deg-
radation product monolyso-CL (MLCL) in mitochondria
[57–60] and promotes OMM permeabilization [61]. During
this process, the peroxidase activity of Cc results in the
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oxidation of CL (to which it is anchored) facilitating the
release of Cc from the IMM and subsequent massive release
into the cytosol at the onset of apoptosis [18, 62]. Extramito-
chondrial Cc molecules interact with a variety of targets in
the cytosol and nucleus, leading to a point of no return in
the programmed cell death regulation [63–77].
3. Cytochrome c Binds Cardiolipin: A Tale of
Grooves, Cavities, and Melting
Cc belongs to the class I single-heme cytochrome c family,
displaying the four typical α-helices conserved in the whole












































Figure 1: Role of cardiolipin in cell homeostasis and apoptosis. (a) Under homeostatic conditions, cardiolipin (CL) facilitates the assembly of
respiratory supercomplexes (brown arrows) and maintains a population of Cc bound to the inner mitochondrial membrane (IMM). The
efficiency of electron transfer is high (thick red arrow). (b) Under apoptotic stimuli, procaspase-8 is recruited to CL-enriched
microdomains in the outer mitochondrial membrane (OMM). The activation of caspase-8 involves cleavage of the BID proapoptotic
factor into two domains, namely, the N-terminal (n-Bid) and C-terminal fragments (t-Bid). Dissociation of these two fragments is
required for the interaction of t-Bid with CL. Then, t-Bid promotes the formation of mitochondrial pores by assembling BAX–BAK
oligomers. At the same time, ROS production increases and Cc acts as a ROS scavenger and pseudoperoxidase. Cc peroxidase activity
results in oxidation of CL acyl chains, to which the hemeprotein is anchored, freeing Cc from the IMM, facilitating its subsequent release
into the cytosol upon OMM permeabilization. The efficiency of electron transfer is low (dashed red arrow). In addition, CL can be
degraded in part, losing one of its acyl chains, giving rise to monolysocardiolipin (MLCL).
3Oxidative Medicine and Cellular Longevity
two of them providing axial ligands for the heme iron. His18
at the proximal side of the heme provides the imidazole
ligand conserved among the class I family. At physiological
pH values, Met80 thioether acts as a distal ligand. The heme
porphyrin ring is covalently bound to the protein backbone
by thioether bonds between the vinyl groups of the porphyrin
and conserved cysteine residues in the CXXCH motif. For
human Cc, conserved cysteine residues are Cys14 and
Cys17. According to hydrogen exchange (HX) experiments,
the apparently simple structure hides five folding units
(called foldons) with different stabilities [79]. The most stable
one (I) comprises the N- and C-terminal α-helices. Foldon II
comprises ΩI (from Thr19 to Phe36) and α-helix 3, which
comes before ΩIII. Foldon III (a.k.a. neck) comprises two
short amino acid stretches with an extended conformation
flanking the ΩII-loop. Notably, the latter faces heme propio-
nates and is the least stable foldon (V), followed by the ΩIII
region (IV) containing Met80.
The low stability of the loop containing Met80, com-
prising the sixth iron ligand, has a crucial role in Cc phys-
iology. Recent ultrafast X-ray spectroscopy analyses have
highlighted the weakness of the Met80-Sδ-Fe
+2 bond and
the lack of stability (4 kJmol-1) provided by the protein
matrix, most likely via hydrogen bonding [80].
At physiological pH, Cc has a net charge of +8 from its
unevenly distributed ionizable groups [81, 82]. This favors
interactions with negatively charged molecules, such as the
polar head of phospholipids, including CL. This interaction
was first analyzed by Kimelberg and Lee, using lecithin-CL
vesicles [83]. Their analysis together with early HX measure-
ments by solid-state nuclear magnetic resonance (ssNMR)
indicated that Cc preferentially binds with CL [84]. They also
suggested that during this interaction, CL destabilizes or
unfolds the hemeprotein. Further relaxation time measure-
ments by 31P NMR showed that Cc impacts CL dynamics
[85]. Surface plasmon resonance and electrochemical exper-
iments on planar lipid bilayers allowed Salamon and Tollin
to propose a two-step mechanism [86–88]. According to
their proposal, Cc first binds to membranes through electro-
static interactions and, subsequently, through hydrophobic
interactions to promote changes in both the structure of Cc
and the membrane. Then, electron paramagnetic resonance
(EPR) and magnetic circular dichroism (MCD) analyses
showed that Cc undergoes structural changes which affect
Fe coordination and result in the appearance of a radical at
high liposome concentrations [89]. Hence, mixing Cc with
lipids may yield several species, found in recent fluorescence
anisotropy analyses [90].
Apparently at odds with this proposed model,
paramagnetic-quenching EPR experiments on horse heart
Cc, spin-labelled at different lysine positions, indicated that
the hemeprotein can weakly interact with 1,2-dioleoyl-sn-
glycero-3-phosphoglycerol (DOPG) bilayers [91]. This study
highlighted three lysine residues at ΩIII (K72, K86, and K87,
a.k.a A-site; Figure 2(a)) adjacent to the DOPG membrane.
Further fluorescence studies using vesicles containing fluo-
rescent lipid probes identified a secondary CL-binding site
at low pH values [93]. Contrary to the A-site, CL association
at this novel region (a.k.a. C-site; Figure 2(a)) is unaffected by
ionic strength or the presence of ATP. Data suggested CL
binds to this site via hydrogen bonds at N52, and a single acyl
chain of the phospholipid inserts into a nearby hydrophobic
pocket while the others remain in the bilayer [94]. This pro-
posed interaction mechanism is known as the extended lipid
anchorage model and is supported by studies on the ability of
natural and engineered phospholipids to quench the fluores-
cence of Zn-substituted Cc [95, 96]. Consistently, a N52I
mutation heavily impacts the kinetics of the interaction
between Cc and CL in CL-containing liposomes [97].
While, a combination of lysine modification, tryptic
digestion, and MALDI-TOF analysis unveiled that horse
heart Cc promotes the fusion of lipid vesicles via an interac-
tion at a second positive patch. This region (L-site) comprises
K22, K25, K27, H26, and H33, besides the previously
reported A- and C-sites (Figure 2(a)) [98].
An additional UV-Vis analysis showed slight differences
in the binding kinetics within a set of yeast Cc mutants




































Figure 2: Cardiolipin-binding sites in cytochrome c. (a) Ribbon representation of oxidized human Cc (PDB 2N9J) [92]. CL-binding sites are
highlighted in orange (A-site or distal productive), green (L-site or proximal productive), purple (C-site), and cyan (N-site or proximal
unproductive). The heme axial ligands H18 and M80 are highlighted as well. (b) Side chain representation of the positively charged Cc
residues involved in the formation of the Cc-CL complex. Residues marked with an asterisk are reported to constitute the L- and N-sites.
(c) Side chain representation of hydrophobic Cc residues, which ensure the tight interaction between Cc and CL acyl chains.
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the protein (PDB 1AKK; [100]), the authors proposed a
cleft defined by the ΩIII residues K72, K73, K86, and
R91, matching A-site. Building on from this data, the ability
of site-directed mutants of horse heart Cc to bind CL-
containing liposomes was tested [101]. Notably, substituting
K73 and K79 with asparagine alters the affinity of Cc towards
these liposomes, whereas the same mutation at position 72
does not.
A common feature of these binding sites is the presence
of several positively charged and hydrophobic residues
(Figures 2(b) and 2(c)). In line with Tollin and Salamon’s
early postulates [88], the interaction between the positively
charged residues of Cc and negatively charged phosphate
groups of CL initiates the formation of the Cc-CL complex
driven by electrostatic interactions [101–104]. After the initi-
ation of the complex, hydrophobic Cc residues play a key role
in the interaction with CL acyl chains, thereby establishing a
tight binding between Cc and CL [15, 105].
A strong piece of evidence supporting the extended
anchorage hypothesis is the presence of a channel formed
by residues 52 to 74 in the tuna Cc XRD structure [81], where
the highlighted cavities are only visible in the 4Å model. An
attempt to manually dock CL inside the structure of horse
heart Cc yielded two acyl chains within the backbone [97].
Any assessment of clashes of these two acyl chains with inter-
nal residues was missing. Nevertheless, none of the two cav-
ities in this structure appear in the updated structure at 1.5Å
resolution (PDB 5CYT; unpublished). Hence, the extended
lipid anchorage model demands that Ccmust undergo a sub-
stantial conformation change when interacting with lipid
vesicles. A low-resolution analysis using monoclonal anti-
bodies suggested that lipid-bound Cc displayed an alkaline-
like conformation [106]. The alkaline form of oxidized Cc
presents a conformation different to that of the native spe-
cies, which relates to an exchange between the Met thioether
ligand and a Lys amine. However, to our knowledge, the only
Cc alkaline structure available (PDB 1LMS; [107]) lacks a
channel in which the acyl chain may be lodged, although
the heme moiety is more accessible to solvent than the native
structure. Another possibility is the formation of Cc oligo-
mers by domain swapping [108, 109]. Although these struc-
tures are highly variable depending on how the domain
swapping is triggered by experimental conditions, a recent
analysis has shown they are capable of encompassing an acyl
chain [110]. Furthermore, Tyr67 in these structures would
face C11 of docked linoleic (18 : 2
Δ9,12) acid, a finding in
agreement with peroxidation mechanisms. However, evi-
dence of Cc oligomerization in the presence of membranes
remains unavailable.
Many of the studies above report the loss of the Met80
coordination and at least partial denaturation—or transition
to a molten globule state—of Cc when binding to CL-
containing vesicles or liposomes [15, 84, 93, 95–97, 109–
111]. Aside from CL, some other lipids can elicit similar such
structural changes in Cc [105]. This makes the heme moiety
more accessible to small substrates such as carbon monoxide
or nitric oxide [105, 111]. Moreover, time-resolved fluores-
cence resonance energy transfer (trFRET) experiments
show labelled residues—not previously reported to bind
CL—moving further away from the heme group in the
presence of CL-containing liposomes [103, 112]. Further-
more, changes in the CD spectra and Trp59 fluorescence
indicate unfolding of at least the lowest energy foldons.
Consistent with the loss of Met80 coordination, substantial
negative shifts in the midpoint potential of Cc are observ-
able in the presence of lipid vesicles [113, 114]. Disruption
of the Fe-Met80 bond also correlates with a substantial
increase in Cc peroxidase activity when Cc interacts with
CL-containing vesicles [15, 105, 113]. An illustration of
conformational changes, adapted from Muenzner et al.
[112], is available in Figure 3(a).
The current understanding of the effects of lipid binding
on Cc structure (as described above) is controversial. For
instance, depending on the nature of the CL-rich membrane
preparations and experimental setup, the shift in redox
potential can be positive [86] or negative [113, 114]. Recently,
Wand and collaborators demonstrated that the mitochon-
drial crypts are concave surfaces, opposed to the convex
lipoic vesicles often used in the analyses. They then analyzed
the solution structure of oxidized horse heart Cc encapsu-
lated in reverse lipid micelles by NMR [115]. They utilized
pseudocontact shifts as experimental restraints, which are
highly sensitive to distances and orientation with respect to
the main axes of the iron coordination sphere. An overlay
of the structures of free [100] and encapsulated horse Cc
[115] (PDB 1AKK [100] and 2N3B [115], respectively) are
shown in Figure 3(b). Notably, the structure of Cc remains
unaltered, and the chemical-shift perturbation map [115]
resembles that observed for interactions between Cc and its
protein targets [116] and other class I single-heme cyto-
chrome c family members [117]. In fact, this patch includes
a novel region (N-site), not previously reported, compris-
ing F36, G37, T58, W59, and K60, besides the known res-
idues of the A- and L-sites (Figure 2(a)). Surprisingly,
ssNMR spectra tracking the interaction between Cc and
small unilamellar (convex) vesicles showed no feature indi-
cating formation of either a molten globule or unfolding
[118]. Consistently, solution HSQC (NMR) spectra of
horse heart Cc in the presence and absence of similar ves-
icles overlapped quite well [119]. Although some signals
broaden, while others were displaced—as expected for this
interaction—no features of unfolding are apparent. There-
fore, the overall curvature or the membrane may be irrele-
vant for the stability of bound Cc. Previous data on Cc
unfolding in the presence of lipid vesicles might be reviewed
in regard to membrane composition, lipid stability, and
experimental setup. For instance, the dynamics of Cc can
change depending on buffer conditions [119]. Similarly, the
ionization state of CL also affects Cc binding [120].
Understanding the entire landscape of the data requires
the rationale underpinning the studies to be taken into
account. An equilibrium between unbounded native Cc spe-
cies and membrane-bound populations—by either weak
electrostatic interactions, hydrogen bonding, or hydrophobic
interactions—can be observed. The relative weights of such
populations vary with experimental conditions. Further-
more, our ability to detect different species relies on the sen-
sitivity of each biophysical approach. As recently pointed out,
5Oxidative Medicine and Cellular Longevity
many of the analyses above suffer from low-resolution data
or the introduction of probes that could partially alter results
[118]. Therefore, full understanding requires complete
knowledge of experimental conditions.
4. Interplay between Lipid and Cytochrome c
Dynamics: The Compact/Extended Model
Cc can undergo several structural transitions triggered by
changes in experimental conditions such as pH [89, 90,
121–123]. For example, low-spin (S = 0) FeII species may
turn into high-spin (S = 2) species in the presence of lipo-
somes, as shown by EPR and MCD spectroscopies [89].
Notably, ionic strength and lipid-to-protein (L/P) ratio
strongly influence the populations of the distinct species
[15, 110, 124, 125]. These ratios relate to lipid surface cover-
age by Cc molecules [125, 126]. At low L/P ratios the Cc-
coated micelles undergo coalescence—forming giant unila-
mellar vesicles—and precipitate. Whereas at moderate L/P
ratios, Cc promotes interactions between small unilamellar
vesicles [125, 127].
The dynamic of the Cc heme group is highly sensitive to
spin state, axial ligand strength, and conformational changes.
Therefore, Raman spectroscopy studies have been key in
unveiling the complexity of Cc conformation equilibria
under different conditions [123, 125–128]. Hildebrandt and
collaborators detected native (B1; His-Met coordination)
and altered (B2) states in the presence of DOPG vesicles
[125]. The B2 state comprises different species: a low-spin





































Changes in protein dynamics
(b)
Figure 3: Proposed model for the interaction of cytochrome c with cardiolipin at pH values above 7. (a) Upper: structure of free Cc showing
the foldon units (in red scale, PDB 1AKK [100]). Lower: the Cc-CL interaction promotes unfolding of the metalloprotein and dissociation of
the axial ligand M80, thus increasing accessibility to the heme crevice. (b) Upper: structural comparison of free (in red scale, PDB 1AKK
[100]) and CL-bound Cc (in blue scale, PDB 2N3B [115]). Lower: interaction of Cc with CL yields a slight difference in dynamics at the
level of the Ω-loops and helix-I. The different foldon units of Cc are colored as a gradient from the most stable (dark colors) to the
weakest region (light colors). The heme group is in green, and the iron atom in orange.
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species (a pentacoordinated (B2[5cHS]) and a hexa-
coordinated species (B2[6cHS])) in which a water molecule
acts as the sixth ligand. The populations of the different states
change according to the L/P ratio. The B2 species predomi-
nates at high L/P ratios, whereas native B1 and His-His-
coordinated B2[6cLS] coexist at lower ratios. These states
are also detectable by MCD [114]. The B2 bis-His-
coordinated species is detectable when Cc is absorbed onto
self-assembled monolayers, with and without CL [129]. At
increasing concentrations of DOPC/tetraoleoylcardiolipin
(TOCL) micelles, the population of bis-His species increases,
as confirmed by His-by-Asn mutations and spectroscopic
analyses [130].
In addition to the L/P ratio, the content of CL and its
composition influence Cc affinity and dynamics in the
bound state. Fluorescence data has indeed revealed that
increasing amounts of CL favors Cc binding to mem-
branes [120]. The theoretical analysis therein suggests that
the protonation state of CL may have a strong influence
on populations of distinct membrane-bound Cc species.
However, the authors acknowledge that the formalism
does not include the effects that Cc exerts on CL distribu-
tion or membrane state (see below). Indeed, kinetic inves-
tigations have shown that the exchange rate between a
native-like, compact (C) and the “extended” (E) conforma-
tions correlates with the amount of CL in the vesicles
[131]. A more recent spectroscopic analysis on titration
experiments by Pandiscia and Schweitzer-Stenner resulted
in similar conclusions [90]. Additionally, the study
highlighted that the L/P ratio also affects the relative
weight of electrostatic interactions, hydrogen bonds, and
hydrophobic interactions—according to ionic strength
series. In summary, besides governing Cc conformational
states, the L/P ratio modulates the nature of bilayer-
protein interactions. Notably, all the studies highlighted
above hint at a rather peripheral binding model, with little
or no embedding of Cc into the membrane [90, 123, 125,
126, 128, 129, 131].
On theotherhand,Ccdoes exert a strong influenceon lipid
head-group dynamics, as revealed by early 31P ssNMR studies
whichdemonstrated an increase in acyl chains dynamics and a
restraint in the polar head groups of phospholipids [132, 133].
Interestingly, Cc has little impact on the 31P ssNMR “powder”
spectra of dioleoyl-phosphatidylcholine (DOPC), dioleoyl-
phosphatidylethanolamine (DOPE), or DOPC/DOPE vesi-
cles not containing CL [134]. Indeed, NMR data strongly
supported CL undergoing phase separation—to form CL
rafts—within mixed DOPC/CL preparations upon the
addition of Cc [132, 135]. Further, freeze-fracture electron
microscopy images highlighted the ability of Cc to promote
the transition of phospholipid bilayers containing CL into
non-bilayer structures, including inverted tubular (HII) states
[133, 134]. A full isotropic signal in the 31P ssNMR spectra
of phospholipid preparations in the presence of Cc evinced
the formation of vesicular or micellar structures when the ves-
icles contained CL [132, 136]. Similarly, a downfield broad sig-
nal indicated that CL mediates the formation of the HII phase
upon the addition of Cc. In this sense, molecular dynamics
simulations in which Cc is in contact with a DOPC/CL mem-
brane highlight the ability of this protein to recruit CL into
rafts [118]. In addition, Cc can induce local changes in mem-
brane curvature when the ratio of CL increases up to 20%. Fur-
thermore, Cc induces pore formation in DOPC/CL giant
unilamellar vesicles (GUV), as shown by confocal microscopy
[137]. These pores are wide enough to allow Cc and dextran
molecules to cross the membrane.
Nevertheless, the ability of Cc to induce membrane
changes seems to be secondary regarding the activation of
peroxidase activity. Addition of Cc to large DOPC/CL unila-
mellar vesicles at a ca. 6 CL/Cc ratio promotes peroxidase
activity without substantially affecting 31P ssNMR spectra
or the 13C frequencies of the lipid glycerol signals [138].
The major population—those accounting for less than
10% of the protein are not detectable—of Cc in these
experiments displays the same structure as the native pro-
tein in solution. Chemical-shift perturbation analysis
revealed that residues affected include the ΩIII-loop and
some nearby residues (including A-site residues). However,
changes in the dynamics of the ΩIII-loop as it couples with
bilayer motions are observable. This, rather than an overall
unfolding, is sufficient to trigger the peroxidase activity under
these conditions. In accordance with this finding, the pertur-
bation pattern shifts when the temperature is changed or
when the vesicle phospholipids are unsaturated.
The formation of Cc-CL complex requires approxi-
mately 6 molecules of CL per Cc molecule [15, 112, 119,
138, 139]. The values of the apparent dissociation equilib-
rium constant for the Cc-CL-reduced complex are in the
low micromolar range (1.4μM at pH 8.1 and 2.2μM at
pH 6.5) [140], whereas in the oxidized form, they are in
the high micromolar range in a two-step reaction (20μM
and 42μM) [102]. Nevertheless, binding constants depend
on CL composition. The affinity of Cc towards tetra-
stearyl-cardiolipin-containing vesicles is several fold higher
than that for TOCL ones [102], whereas tetra-myristoyl-
cardiolipin barely interacts Cc [15]. Notably, the measured
affinities correlate well with the peroxidase activity of Cc
in the presence of the respective vesicles, rather than the
degree of unsaturation in the acyl chains [102].
5. Cardiolipin Oxidation by Cytochrome c
CL is particularly sensitive to auto-oxidation processes—those
directly initiated by inducers, such as ROS. The proximity of
its four unsaturated acyl chains allow “arm-to-arm” propaga-
tion, enhancing its reactivity [141]. Auto-oxidation takes
place in several steps. A free radical (e.g., a ROS molecule)
contains an unpaired electron, and this semioccupied orbital
is a sink for a second electron. Polyunsaturated fatty acids
(PUFA), such as linoleic or linolenic composing CL, are par-
ticularly sensitive to ROS-induced oxidation due to conjuga-
tive effects. Radicals such as superoxide, peroxyl (ROO•), or
hydroxyl (HO•) sequester a hydrogen atom from the α-meth-
ylene carbon with respect to the first (di-) vinyl group. The
resulting radical reacts immediately with O2 to generate a
peroxyl radical. The variation of electron vacancy in the lipid
radical underlies the diversity of reaction products. No mat-
ter how the lipid radical originates, it tends to propagate via
7Oxidative Medicine and Cellular Longevity
a reaction with molecular oxygen, water, or other lipids.
Within the process of CL signaling, there are several reac-
tions which stand out including the addition of oxygen
(to form peroxides), transfer of hydrogen atoms, addition
of peroxyl radicals, and intramolecular peroxide substitu-
tion [142].
Oxidative phosphorylation and certain mitochondrial
enzymes are sources of O2
-• radicals [143]. Superoxide is
highly soluble in lipids but can be reduced within membranes
by tocopherol and quinone and eliminated by superoxide
dismutase (SOD), which transforms two superoxide mole-
cules into a molecular oxygen and hydrogen peroxide
[144]. In fact, enzymes like SOD, catalase, and peroxidases
take part in active cell defense against oxidative stress [144].
H2O2 is a strong oxidant—the reduction potential for the
H2O2/H2O pair is +1.35V, at pH 7—but kinetically ineffi-
cient. However, the presence of iron chelates under certain
pathological conditions can enhance H2O2 efficiency through
Haber-Weiss-like reactions (see Equations (1)–(3)) [145]:
Fe3+ + H2O2 ⟶ Fe2++O−∙2 + 2H+ ð1Þ
Fe2+ + H2O2 ⟶ Fe3+ + HO−+HO∙ Fenton’s reaction
  ð2Þ
O−∙2 + Fe3+ ⟶ Fe2+ + O2 ð3Þ
The hydroxyl radical product is highly reactive, sequester-
ing hydrogen atoms from available substrates. The resulting
carbon-centered radicals may react with molecular oxygen to
generate (hydro-) peroxides (Equations (4)–(6)):
HO∙ + RH⟶H2O + R∙ ð4Þ
R∙ + O2 ⟶ RO∙2 ð5Þ
RO∙2 + H+ + Fe2+ ⟶ ROOH+ Fe3+ ð6Þ
Nevertheless, homeostatic cells exert a tight control over
metal chelation to avoid Fenton’s reactions. Indeed, a set of
antioxidant agents prevent a surge in the levels of ROS. Hence,
except for pathological conditions, H2O2 requires the activity
of peroxidases to function efficiently as an oxidant. Within
the IMM, Cc displays both peroxidase and oxygenase activi-
ties, the latter promoting CL oxidation, while sparing other
phospholipids [18, 146]. This event is crucial for the release
of mitochondrial proapoptotic factors into the cytoplasm [18].
5.1. Peroxidase and Oxygenase Activities of Cytochrome c (Dr.
Jeckyll and Mr. Hyde). Heme peroxidases constitute a vital
and ubiquitous group of heme enzymes catalyzing the two-
electron oxidation of substrates using H2O2 as the ultimate
electron acceptor [147, 148]. In canonical peroxidases,
H2O2 is added to the pentacoordinated, high-spin Fe
III. The
resulting state—Compound I—is two oxidation equivalents
above the resting state and is reduced back to the resting con-
figuration in two steps through Compound II. Both states,
Compounds I and II, are high valence oxoferryl (FeIV) deriv-
atives, but the first comprises an additional π-cation radical
(see Equations (7)–(9)) (Figure 4) [147].
Heme FeIII
 





Heme O = FeIV−R∙+
 
CompI





Heme O = FeIV
 































Figure 4: Peroxidase and oxygenase activities of cytochrome c.
Reaction model merging the proposal from Kagan and
collaborators [149] and the adapted catalytic model of
cyclooxygenases as reviewed by Marnett [150]. Blue arrows
correspond to the canonical peroxidase cycle [146]. Heterolytic
cleavage of a peroxide substrate—preferentially for Cc, a lipid
hydroperoxide—yields the corresponding hydroxyl derivative (or
water when the substrate is H2O2) and Compound I, which is
reduced back to the resting ferric state in two sequential single-
electron transfers from A substrate. Red and green arrows indicate
the reactions purportedly leading to oxygenase activity according
to the literature. Spin trap experiments have detected Y48 radicals
[151]. Dimers of tyrosines 67 and 74 and oxidation products of
Y48 are detectable even in the absence of H2O2 [152]. The tyrosyl
radical sequesters a hydrogen atom from an unsaturated fatty acid.
Finally, O2 reacts with the alkyl radical to form an alkyl peroxide
radical as an initial product undergoing further reactions.
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In true peroxidases, a histidine residue acts as an acid-
base catalyst at the distal side of the heme ring, while a highly
conserved arginine residue stabilizes the alkoholate leaving
group to favor the heterolytic cleavage of the peroxide O–O
bond [153]. The orientation of these residues and the
hydrogen-bond network at the heme distal side are critical
for efficient formation of Compound I [154]. As recently
pointed out by Vlasova [148], the composition of a true per-
oxidase active site prevents its damage by highly oxidizing
intermediate compounds.
Cc and other hemeproteins can act as pseudoperoxidases;
that is, under only certain stimuli they show peroxidase activ-
ity [148, 155]. Contrary to true peroxidases, the surroundings
of hememoiety are unprotected against oxidation, so the per-
oxidase activity ends up damaging the protein. In the early
1990s, Radi and collaborators reported the ability of Cc to
oxidize small compounds in solution [145] and to carry out
lipid peroxidation [146] in the presence of H2O2. Neverthe-
less, the reactivity of Cc towards H2O2 was low, as it requires
the absence of the sixth ligand. Thus, the Km value for H2O2
was very high—ca. 65mM. In this sense, oxidative reactions
showed a time lag after the addition of H2O2, indicative of
an activation step. Moreover, peroxidase activity in solution
decayed at pH values higher than 8 [145]. Poor reactivity
may also result from the absence of histidine at the distal site
(vide infra), as it is an acid-base residue “pumping” the het-
erolytic cleavage of H2O2 during Compound I formation.
Based on chemiluminescence analyses of the reaction,
Chance and coworkers proposed a homolytic reaction mech-
anism (Equations (10)–(12)) [156], supported by EPR spin
trap studies of small organic hydroperoxides [157].
Heme FeIII
 
+H2O2 ⟶Heme HO∙ − FeIII
  ð10Þ
HO∙ +H2O2 ⟶H2O +HO∙2 ð11Þ




+ O2 + H2O
ð12Þ
However, EPR spin trap experiments highlighted the
generation of Cc tyrosine radicals upon treatment with
H2O2 [18, 151, 155, 158]. Furthermore, spin trap experi-
ments detecting radical products resulting from oxidation
of different substrates by H2O2 strongly suggested the reac-
tion being mediated by an oxoferryl [O=FeIV] intermediate
[155]. Analysis of the orientation of this radical within the
native state identified a tyrosine residue at the ΩII-loop—na-
mely, Y48 in horse heart Cc and either Y46 or Y48 in human
Cc [159]. The peroxidase activity of Cc in the presence of CL
increases by three orders of magnitude when the driving oxi-
dant is a lipid peroxide instead of H2O2 [149]. Spin trap anal-
ysis of reaction products by Kagan and collaborators
indicates a diversity of catalytic mechanisms depending on
the binding site of the substrate, namely, a homolytic perox-
ide cleavage minority mechanism and a major, heterolytic
mechanism. Notably, the small hydroperoxide substrates
involved in this pathway dock near R38 and H33. However,
how the docked structure undergoes conformational changes
to fulfil all geometrical constraints needed for Compound I
formation remains unclear (Figure 4).
Binding of hydrogen peroxide to the heme iron is a key
step in the reaction mechanism underlying peroxidase activ-
ity. The reactive species need to displace the thioether axial
ligand. This takes place when a strong interaction between
Cc and a membrane induce a substantial conformational
change in the hemeprotein [15, 84, 93, 95–97, 109, 111]. Nev-
ertheless, Kagan and coworkers also detected peroxidase
activity in Cc at low CL/Cc ratios—at which the most interac-
tions are weak electrostatic [15]. Furthermore, they found
that the energy required to activate peroxidase activity is
lower than that required for partial unfolding of the protein.
In fact, as pointed out before, the bond joining iron to the
thioether ligand is quite weak [160]. Thus, “breathing” fluc-
tuations ofΩII- andΩIII-loops may facilitate the replacement
of the thioether ligand by small reactants—such as cyanide,
carbon monoxide, water, or hydrogen peroxide—without
demanding major structural changes. In fact, Cc peroxidase
activity rises in the presence of H2O2 as the concentration
of denaturant increases, as previously observed in a similar
analysis with bacterial cytochrome c550 [161]. Statistical anal-
ysis of activity and unfolding slopes indicate that increasing
the motions of the weakest Ω-loops correlates well with per-
oxidase activity in the “compact” Cc species [162].
The peroxidase activity of Cc can exert a protective role in
mitochondria under certain conditions [11]. Indeed, reduc-
tion of lipoid hydroperoxide compounds to hydroxyl ones
provides a way of relieving oxidative stress in the mitochon-
drial membrane while generating signaling molecules [149].
Moreover, O2
-• reduces nitric oxide (•NO) generated in mito-
chondria under stress to form peroxynitrite (HOONO), a
highly reactive species. Cc-CL complexes have been proposed
to aid peroxynitrite detoxification to yield either nitrate or
nitrite through an oxoferryl state [163].
Conversely, the peroxidase activity of Cc has been impli-
cated in certain pathologies. For instance, oxidation of sulfite
to its radical SO3
-• is a key mechanism in sulfite toxicity
[164]. Moreover, Cc mediates the formation of tyrosine rad-
icals responsible for α-synuclein dimerization [66, 165],
which leads to the development of the Lewy body diseases.
Canonical peroxidase activity involves two sequential
one-electron oxidation steps and no transfer of oxygen from
the oxoferryl complexes to the substrate [146]. Nevertheless,
Compound I in certain heme enzymes—such as cytochrome
P450—can transfer oxygen to certain substrates yielding
hydroxy-derivatives. Interestingly, hydroxy-derivatives of
CL cannot undergo peroxidation and inhibit the release of
Cc [166]. Altogether, considering the findings above con-
cerning tyrosyl radicals in Cc [151], Kagan and collaborators
proposed that Cc acts as an oxygenase to produce CL perox-
idation [167]. This activity would also be responsible for
phosphatidylserine peroxidation affecting the plasma mem-
brane during apoptosis [65]. This hypothesis suggests that
hydrogen is transferred to Compound I from a nearby tyro-
sine residue to yield oxoferryl Compound II and the afore-
mentioned tyrosyl radical (Figure 4). This mechanism is
similar to that proposed for cyclooxygenases, in which a
hydrogen atom is sequestered from an acyl chain, generating
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a carbon-centered radical capable of reacting with molecular
oxygen [150].
Unlike true peroxidases, the environment of the heme
moiety is unprotected from highly oxidizing species arising
during the catalytic cycle [148]. When reacting with H2O2,
degradation of the heme porphyrin often becomes appar-
ent by a diminution of the Soret band intensity [146,
156]. A thorough mass spectrometry analysis of Cc residue
adducts derived from H2O2 has been carried out by Flem-
mig and collaborators [152]. Several oxidation reactions
can occur to produce a methyl-sulfoxide derivative from
the methionine thioether, a sulfonic acid derivative from
cysteines and 2-oxohistidine from histidine. While tyrosine
residues can covalently cross-link or undergo oxidation to
dihydroxyphenylalanine (DOPA) and subsequently to qui-
nones, lysine residues can undergo carbonylation [152, 168,
169]. These changes occur when H2O2 is added to Cc sam-
ples [80, 152, 170–173].
Remarkably, different regions in the protein display dif-
ferent sensitivities to oxidation depending on the environ-
ment. For instance, specific M80 oxidation takes place in
the presence of DOPC/DOPE micelles [174]. The ΩIII-loop
is the first to be affected, whereas foldon I (helices I and IV)
is the least affected by oxidation. Notably, the peroxidase
activity of Cc increases in a time-dependent manner upon
the addition of H2O2. Such increments in peroxidase activity
may result from successive oxidation of M80 and lysine res-
idues, as proposed by Yin and Konermann [80, 170]. Indeed,
M80 oxidation promotes conformation exchange in Cc
which impacts on heme ligation. With time, oxidative dam-
age extends to the porphyrin ring, releasing iron capable of
performing Fenton’s reactions [173]. Finally, it is worth not-
ing that CL peroxides can induce at least some of these oxida-
tive PTM [152].
5.2. The Alkaline Transition of Cytochrome c and Peroxidase
Activity. As mentioned above, previous data obtained using
monoclonal antibodies highlighted that an alkaline-like
conformation could interact with CL and exit mitochondria
during apoptosis [106]. These antibodies also recognize the
M80A mutant in the cell nucleus [175]. Notably, this
mutant displays enhanced peroxidase activity. In addition,
the peroxidase activity of Cc is somewhat pH dependent
[145, 176]. Indeed, for horse heart Cc, peroxidase activity
increases at acidic pH values [177] and slows beyond pH
8 [145]. Furthermore, the ability of Cc to oxidize O2
-• falls
at pH values above 7 [7]. The affinity of Cc towards mem-
branes and the interaction patch involved also depend on
pH [15, 98, 120, 127]. These effects illustrate how pH-
dependent conformation changes modulate the different
activities performed by Cc.
A number of mutations and PTM have been reported to
simultaneously affect the peroxidase activity of Cc while
bringing the so-called alkaline transition to lower even phys-
iological pH values [178–182]. Loss of M80 coordination is
evident from NMR spectra and UV-Vis spectra in all these
studies. Cc peroxidase activity requires the heme iron to be
pentacoordinated; the relationship with the pKA of the alka-
line transition could be attributable to the lysine amine being
weaker than methionine thioether in the ligand. However, at
a neutral pH, lysine is a stronger ligand than methionine
[183]. In fact, horse heart and human Cc show lower perox-
idase activities at alkaline pH values [145, 182]. Moreover,
mutation M100K in P. versutus cytochrome c550 makes the
protein more stable at neutral pH while decreasing its perox-
idase activity 20-fold [183].
Nevertheless, the shift in the alkaline transition towards
lower pH values indicates destabilization or higher dynamics
in the ΩII- and ΩIII-loops in the Met-coordinated species.
Given the weakness of the thioether ligand bond towards
iron, increasing fluctuations of these loops will increase the
population of high-spin species and/or alternative low-spin
(e.g., bis-His) species below the pKA value of the transition.
This is observable in phosphomimic mutants, as well as in
nitrated species of Cc [178–180, 184–186]. Furthermore,
enhanced dynamics facilitate the access of small substrates
to the heme iron [162].
5.3. Control of Cardiolipin Oxidation by Post-translational
Modification of Cytochrome c. Protein PTM regulate tightly
controlled cellular processes and increase the functional
diversity of proteins, often acting as a cell response switch.
Several post-translational modifications modulate Cc struc-
ture and functionality, such as sulfoxidation [187], carbonyl-
ation [152], homocysteinylation [188], nitration [179, 180],
and phosphorylation [189] (Figure 5). Phosphorylation of
tyrosine residues is associated with many human patholo-
gies including cancer, ischemia, asthma, and sepsis. As
highlighted earlier, tyrosine radicals are key for the oxy-
genase activity of Cc [157]. Thus, the amount of hydroxyl
products from TOCL oxidation is lower when Y48E phos-
phomimic species instead of WT Cc acts as a catalyst
[190]. Additionally, tyrosine phosphorylation impairs the
formation of radicals, preventing dimerization [191]. This
fact may be critical in pathological processes such as
Parkinson’s disease [66]. Therefore, the PTM that affect
these residues are key in regulating Cc activity.
Given the difficulty in preserving the phosphorylation
state of Cc outside of cell extracts, a common strategy to
investigate consequences of phosphorylation is to mimic
the modification by site-directed mutagenesis. All phos-
phomimetic Cc species, except a mutant at position 97,
display altered affinity towards cardiolipin [178, 186, 190,
192–195]. The peroxidase activity of both free Cc and
Cc-CL complexes increases in the phosphomimetic T28D
and Y48pCMF. However, for the Y48E species, the increase
only occurs with the free protein (Table 1) [178, 190, 192,
194]. In addition, at a high CL/lipid ratio, the peroxidase
activity of the T28E mutant decreases [195]. A possible
explanation may be that the greater population of CL versus
other lipids in the liposome composition promote unfolding
of the hemeprotein, acting as an off switch (Table 1) [131].
Hence, the negative charge at these positions could induce
structural changes in the heme crevice which allow greater
accessibility for hydrogen peroxide (Figure 5).
Peroxynitrite generated during nitrooxidative stress is a
powerful amino acid modifier, affecting tyrosine residues
among others [201]. Common products of the reaction
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between tyrosine and HOONO are 3,5-dinitrotyrosine, 3-
nitrotyrosine, tyrosine radicals, and dityrosine. Neverthe-
less, treatment of Cc in vitro with peroxynitrite yields its
3-nitrotyrosine adducts, with the nitro group attaching to
one of the Cε of the aromatic ring [202]. Nitration affects
the redox potential of Cc as well as its electron-exchange
kinetics, depending on the residue involved [203]. The
nitration of Y46, Y48, Y74, and Y97 residues also increases
the peroxidase activity of Cc and lowers the pKA value of
the alkaline transition besides other functional properties
[179, 180, 183, 185, 197, 204, 205] (Table 1). Nitration
of Cc has been associated with several diseases, including
chronic nephropathy [206].
All modifications/mutations of S47 and Y67 alter the per-
oxidase activity of Cc [79, 179, 185, 192, 195, 197]. Y67 is
located close to Met80 and is part of the hydrophobic pocket
which houses the acyl chains of CL. This residue is also key
for the stability of the ΩIII − loop (Table 1).
Homocysteinylation is a PTM that involves the covalent
bonding of a homocysteine thiolactone—an intermediate
metabolite of methionine metabolism—with a lysine residue
[188]. Upregulation of this PTM is implicated in several
human pathologies including cancer and cardiopathies
[198, 207]. The degree of homocysteinylation, as well as the
rate at which this modification occurs in the presence of
homocysteine thiolactone, is related to the number of lysine
residues [188]. Human Cc displays a lysine content of
17.1% in its amino acid composition, which makes it sensi-
tive to homocysteinylation. Homocysteinylation of surface
lysines on Cc causes aggregation of the protein. However,
N-homocysteinylated lysines adjacent to the heme cavity
produce conformational changes, disrupt the coordination
of the M80 axial ligand, and alter the redox state of Cc,
reducing the iron of the heme group [196, 208]. These
conformational changes increase Cc peroxidase activity
(Table 1) [209].
As discussed before, Cc is modulated by several oxidative
modifications due to its activity, eventually leading to
changes in iron coordination. One oxidative modification is
the carbonylation of lysine residues, which affects residues
72 and 73, both of which are involved in the alkaline transi-
tion of Cc [170] (Figure 5). Reportedly, successive carbonyl-
ation events at K53, K55, K72, and K73 lead to the
formation of the pentacoordinated Cc species, resulting in
increased Cc peroxidase activity (Table 1) [170]. Similarly,
the sulfoxidation of M80 facilitates the formation of a Com-
pound I-type intermediate that initiates the activity of Cc
peroxidase (Table 1) [171, 210].
5.4. Peroxidase Activity of Cytochrome c and Diseases. Since
the peroxidase activity of Cc relates to the activation of apo-









































































Figure 5: Functional implications of PTM and mutations of cytochrome c. Left: chemical modifications of cytochrome c residues. Right:
ribbon representation of oxidized human Cc (PDB 2N9J) [92]. Residues are colored by type of PTM: pink for nitration, purple for
sulfoxidation, orange for phosphorylation, brown for carbonylation, cyan for N-homocysteinylation, and blue for point mutations. Y48
(asterisk) can be either phosphorylated, nitrated, or mutated for histidine, while Y97 (asterisk) can be phosphorylated or nitrated.
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therapies against certain diseases or pathologies. There are
several examples in the literature that shed light on this topic.
The point mutations Y48H and G41S in Cc cause the
appearance of a special type of thrombocytopenia (thrombo-
cytopenia 4) which is an asymptomatic disorder [199, 200].
Thrombocytopenia 4 is notable for normal platelet produc-
tion. However, in thrombocytopenia platelets are not trans-
ported to the bone marrow and remain in the matrix,
causing the effective platelet content to be lower. Both muta-
tions cause an increase in peroxidase activity, which is related
to an increase in the population of Cc in the pentacoordi-
nated heme state [181, 211, 212] (Table 1).
Most neurodegenerative diseases are associated with cel-
lular stress and apoptotic processes. Due to the double role
played by Cc in the electron transport chain and apoptosis,
it represents an amenable target for the development of ther-
apies against neurodegenerative pathologies. For example,
post-translational phosphorylation of Cc at Y97 is an excel-
lent neuroprotective strategy following brain injury as it
increases the efficiency of electron transport during hypoxic
conditions [193, 213]. Moreover, Cc has been implicated in
the development of Parkinson’s disease—as it colocalizes
with α-synuclein in the Lewy bodies [214]. In fact, the perox-
idase activity of Cc plays an important role in the aggregation
of α-synuclein by tyrosine dimerization [66, 174].
Minocycline is an antibiotic functional against both
Gram-positive and Gram-negative bacteria. Additionally, it
displays neuroprotective properties [215]. The antibiotic
minocycline impairs the interaction between Cc and CL,
inhibiting the activation of peroxidase activity and the
consequent release of Cc into the cytosol to trigger apo-
ptosis [216–218].
Nitric oxide is a well-known inhibitor of Cc peroxidase
activity and thus may downregulate apoptosis [219, 220].
Flavonoids are excellent antioxidants that prevent cellular
aging by ROS scavenger activity. In addition, they can inhibit
Cc peroxidase activity, preventing proapoptotic events [221].
The protection of healthy cells during radiotherapy is
a hot topic. In fact, novel synthetic compounds—e.g.,
imidazole-substituted fatty acids—are currently being trialed
in order to preserve healthy cells by inhibiting the peroxidase
activity of Cc during the irradiation process [222, 223]. These
de novo compounds, mainly imidazole conjugates, block
access to the heme crevice preventing the activation of perox-
idase activity.
Finally, the activation of proapoptotic events, such as the
release of Cc after the peroxidation of CL, may be a good tar-
get for the development of more efficient and specific thera-
pies against cancer [224, 225].
6. Concluding Remarks
In this review, we have outlined major advances and hypoth-
eses regarding the oxidation of CL by Cc. CL oxidation is a
crucial event at the onset of a diverse range of pathologies,
and thus, controlling it has become a key objective of current
research. Targeting Cc—a key player in CL oxidation—has
emerged as an important task.
Since its discovery last century, Cc has displayed great
functional complexity despite its apparently simple structure.
Indeed, its highly dynamic architecture, which enables
conformation changes critical in regulating metabolism,
signaling, and cell fate, still amazes the scientific commu-
nity. Cc interacts with membranes in different ways
depending on their composition and curvature, being able
of modifying the latter. When the hemeprotein interacts
with lipids, it may undergo subtle changes in the dynamics
of its most flexible foldons or may even unfold. A plethora
of factors, including PTM, control these phenomena.
The chemical activity of this protein ranges from the
simplest reactions to diverse and complex reaction mecha-
nisms to drive the oxidation of substrates including CL. In
the recent years, we have witnessed concerted effort to
unveil the intimate chemistry of this process. Solving this
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aDetermined under oxidative stress. bDetermined after peroxynitrite
treatment. cDetermined after chloramine-T treatment. dDetermined after
homocysteine thiolactone treatment.
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conundrum will require us to discriminate minority con-
formations in functional assays and elucidate how this
activity is tuned under distinct conditions. Nevertheless,
knowledge has already amassed on the subject enabling
us to examine the inhibition of CL oxidation, which will
aid the development of translational approaches.
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